Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 2Phase 3 1Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Neoplasm Metastasis 1Melanoma 1

Interventions

Specimen Handling 146pembrolizumab 118Magnetic Resonance Spectroscopy 117Cyclophosphamide 113Biopsy 96fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46Radiotherapy 41venetoclax 40Cetuximab 40fludarabine phosphate 39Paclitaxel 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 32Oxaliplatin 27Leucovorin 27Dexamethasone 26durvalumab 25X-Rays 25Irinotecan 25Radiation 24Cytarabine 23Azacitidine 23Injections 22Temozolomide 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × cediranib × 90 days × Clear all
NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
64 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01364051 2026-04-13

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡